CAR-T therapy in oncology and other fields of medicine

IF 0.2 Q4 ALLERGY

Alergologia Polska - Polish Journal of Allergology Pub Date : 2021-01-01 DOI:10.5114/pja.2021.106685

Amelia Kierasińska, Damian Ciunowicz, Marta Węgierska, E. Stoczyńska-Fidelus, P. Rieske

{"title":"CAR-T therapy in oncology and other fields of medicine","authors":"Amelia Kierasińska, Damian Ciunowicz, Marta Węgierska, E. Stoczyńska-Fidelus, P. Rieske","doi":"10.5114/pja.2021.106685","DOIUrl":null,"url":null,"abstract":"Recently, there has been a breakthrough in immunotherapy. The development of the advanced therapy medicinal product (ATMP) is a striking example of that. Chimeric antigen receptors T cell therapy (CAR-T therapy) is the result of cooperation between biotechnologists, oncologists and immunologists. This article deals with the issues related to the development of CAR-T technology. The basics of CAR-T design and the mechanism of this therapy action are discussed. Its successes were indicated mainly in the treatment of patients with leukemias and lymphomas. EGFRvIII as an exemplary target for the therapy of solid tumors is described. However, it was pointed out what difficulties the therapy against mutated variant of epidermal growth factor receptor EGFRvIII-positive cells encounters. The growing importance of PSMA and GD2 as targets for CAR-T was also pointed out. New trends in this technology, such as the next generations of CAR-T and development of CAR-M, were noticed. Finally, the potential of CAR-T treatment in non-cancerous diseases, such as cardiac diseases, allergies or infectious diseases, including COVID-19, was characterized.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2021.106685","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 1

Abstract

Recently, there has been a breakthrough in immunotherapy. The development of the advanced therapy medicinal product (ATMP) is a striking example of that. Chimeric antigen receptors T cell therapy (CAR-T therapy) is the result of cooperation between biotechnologists, oncologists and immunologists. This article deals with the issues related to the development of CAR-T technology. The basics of CAR-T design and the mechanism of this therapy action are discussed. Its successes were indicated mainly in the treatment of patients with leukemias and lymphomas. EGFRvIII as an exemplary target for the therapy of solid tumors is described. However, it was pointed out what difficulties the therapy against mutated variant of epidermal growth factor receptor EGFRvIII-positive cells encounters. The growing importance of PSMA and GD2 as targets for CAR-T was also pointed out. New trends in this technology, such as the next generations of CAR-T and development of CAR-M, were noticed. Finally, the potential of CAR-T treatment in non-cancerous diseases, such as cardiac diseases, allergies or infectious diseases, including COVID-19, was characterized.

查看原文本刊更多论文

CAR-T疗法在肿瘤学和其他医学领域的应用

最近，免疫疗法有了突破。先进治疗药物(ATMP)的发展就是一个显著的例子。嵌合抗原受体T细胞疗法(CAR-T疗法)是生物技术专家、肿瘤学家和免疫学家合作的结果。本文论述了CAR-T技术发展的相关问题。本文讨论了CAR-T设计的基本原理和这种治疗作用的机制。它的成功主要表现在治疗白血病和淋巴瘤患者。EGFRvIII作为实体肿瘤治疗的示范靶点被描述。然而，研究人员指出，表皮生长因子受体egfrviii阳性细胞的突变变体治疗遇到的困难。还指出PSMA和GD2作为CAR-T靶点的重要性日益增加。人们注意到这项技术的新趋势，如下一代CAR-T和CAR-M的发展。最后，对CAR-T治疗非癌性疾病(如心脏病、过敏或包括COVID-19在内的传染病)的潜力进行了描述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alergologia Polska - Polish Journal of Allergology ALLERGY-

自引率

50.00%

发文量

期刊介绍： Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.